|
WO2021056077A1
|
|
Therapeutic dendrimer
|
|
WO2021035310A1
|
|
Targeted dendrimer conjugates
|
|
WO2020107078A1
|
|
Dendrimer for therapy and imaging
|
|
WO2020102852A1
|
|
Therapeutic dendrimer
|
|
AU2019306745A1
|
|
Therapeutic dendrimer
|
|
US2018326081A1
|
|
Macromolecules
|
|
WO2017190193A1
|
|
Method of prophylaxis of zika virus infection
|
|
CN108884018A
|
|
Dendritic and its preparation
|
|
EP3152248A1
|
|
Dendrimer-drug conjugates
|
|
US9585387B1
|
|
PEHAM dendrimers for use in agriculture
|
|
US2016220689A1
|
|
Macromolecules of dendrimer-platinum conjugates
|
|
CN105007910A
|
|
Method of treatment or prophylaxis of infections of the eye
|
|
KR20140041678A
|
|
Macromolecules
|
|
EP2709633A1
|
|
Method of treatment or prophylaxis of bacterial vaginosis
|
|
US2010324146A1
|
|
Dendrimeric Enzyme Inhibitors
|
|
CN101516969A
|
|
Targeted polylysine dendrimer therapeutic agent modified macromolecule 2
|
|
WO2008017122A1
|
|
Polylysine dendrimer contrast agent
|
|
CN101405010A
|
|
Contraceptive composition
|
|
AU2006308511A1
|
|
Macromolecular compounds having controlled stoichiometry
|
|
WO2007082331A1
|
|
Modified macromolecule
|
